Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid in Beta-Thalassemia Major-Induced Osteoporosis
NCT03040765Phase 3Terminated
- Sponsor
- Hamad Medical Corporation
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in osteoporosis, sponsored by Hamad Medical Corporation. Started May 2018; status: terminated.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03040765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040765.